Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENTRUST
2023-503576-25-00Phase 3Completed
- Sponsor
- 89bio
- Start
- Aug 2023
- Modality
- Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 18
01
Overview
Phase 3, randomised, double-blind trial in hypertriglyceridemia comparing Pegozafermin with Placebo (2 arms). Primary endpoint: Percent change from baseline in fasting triglycerides at Week 26. Started Aug 2023; status: completed.
02
Drugs
pegozafermin
03
Conditions
hypertriglyceridemia
Beyond the preview
Go deeper on 2023-503576-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503576-25-00.